NICE in draft guidance does not recommend the combination of Keytruda + Inlyta to treat renal cell carcinoma. Merck Inc.+ Pfizer
Related news and insights
Nektar Therapeutics and Bristol Myers Squibb announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.
The UK NICE committee has published guidance recommending Opdivo (nivolumab), from BMS, with Yervoy (ipilimumab) within its marketing authorisation as an option for untreated advanced renal cell carcinoma in adults whose disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and only if the company provides nivolumab with ipilimumab according to the commercial arrangement.
Eisai and Merck & Co., Inc., announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus Keytruda the anti-PD-1 therapy from Merck & Co., Inc., for radically unresectable or metastatic renal cell carcinoma (RCC).